BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30007958)

  • 1. Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients.
    Gruber-Rouh T; Kamal A; Eichler K; Naguib NN; Beeres M; Langenbach M; Vogl TJ
    Oncol Res Treat; 2018; 41(7-8):438-442. PubMed ID: 30007958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.
    Gruber-Rouh T; Schmitt C; Naguib NNN; Nour-Eldin NA; Eichler K; Beeres M; Vogl TJ
    BMC Cancer; 2018 Feb; 18(1):188. PubMed ID: 29444653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
    Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
    Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma.
    Vogl TJ; Naguib NN; Nour-Eldin NE; Farshid P; Lehnert T; Gruber-Rouh T; Engels KS
    Acad Radiol; 2012 Apr; 19(4):434-9. PubMed ID: 22265853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
    Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
    Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
    Gross A; Albrecht T
    Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
    Favelier S; Boulin M; Hamza S; Cercueil JP; Cherblanc V; Lepage C; Hillon P; Chauffert B; Krausé D; Guiu B
    Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1039-46. PubMed ID: 23224215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma.
    Mei J; Li SH; Wang QX; Zhong XP; Lu LH; Kan A; Wei W; Guo RP
    Cancer Med; 2020 Jan; 9(1):62-76. PubMed ID: 31701652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
    Zuo CH; Xia M; Liu JS; Qiu XX; Lei X; Xu RC; Liu HC; Li JL; Li YG; Li QL; Xiao H; Hong Y; Wang XH; Zhu HZ; Wu QF; Burns M; Liu C
    Asian Pac J Cancer Prev; 2015; 16(1):245-51. PubMed ID: 25640360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies.
    Haubold J; Reinboldt MP; Wetter A; Li Y; Ludwig JM; Lange C; Wedemeyer H; Schotten C; Umutlu L; Theysohn J
    Rofo; 2020 Sep; 192(9):862-869. PubMed ID: 32131109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
    Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol.
    Vogl TJ; Oppermann E; Qian J; Imlau U; Tran A; Hamidavi Y; Korkusuz H; Bechstein WO; Nour-Eldin NE; Gruber-Rouh T; Hammerstingl R; Naguib NN
    BMC Cancer; 2016 May; 16():325. PubMed ID: 27215551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.